Trial Profile
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; Natural killer cell therapy (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colon cancer; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Rectal cancer; Soft tissue sarcoma
- Focus Adverse reactions
- 17 Feb 2023 Status changed from active, no longer recruiting to completed.
- 14 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Nov 2022.
- 26 Jul 2021 Status changed from recruiting to active, no longer recruiting.